CooperVision Powers the Next Era of Eye Care with New Global Vision Centre and Major Pipeline Advancements

CooperVision opens The Vision Centre in Southampton to unite science, manufacturing, and commercial teams and accelerate new contact lens innovations.

Rhea-AI Summary

CooperVision (COO) has opened The Vision Centre, a new global innovation hub in Southampton, England, and outlined six accelerated contact lens pipeline advancements.

The company plans to introduce a full 1‑day myopia control lens family, multiple new 1‑day silicone hydrogel (SiHy) technologies, a next‑generation SiHy monthly lens, a differentiated entry 1‑day SiHy product, an advanced 1‑day SiHy toric multifocal lens, and a new toric 1‑day experience for astigmatic patients. The 9,940‑square‑meter facility will house about 350 employees and is designed to link R&D, clinical work, pilot manufacturing, and commercial teams to speed development and commercialization of new eye care solutions.

Market Context

On Sep 9, COO's shares fell 14.67% after a strategic-review release that had already named the Visio...

Analysis

On Sep 9, COO's shares fell 14.67% after a strategic-review release that had already named the Vision Centre opening among CooperVision initiatives; this announcement documents that hub's opening and pipeline updates.

Key Figures

Product advancements: 6 Facility area: 9,940 square meters Employees at site: Approximately 350 employees

Product advancements

6

Announced pipeline advancements

Facility area

9,940 square meters

The Vision Centre

Employees at site

Approximately 350 employees

Planned to be housed at the Centre

Historical Context

1 past event · Latest: Sep 09

1 event

1. Sep 09

   Strategic review

   24h Move

   -14.7%

   Previously identified the Vision Centre opening as an operational innovation initiative.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

myopia control, silicone hydrogel, toric, multifocal

4 terms

myopia control medical

"1-day contact lenses for myopia control"

Therapies and products designed to slow the progression of nearsightedness (myopia) in children and adolescents, including specially formulated eye drops, contact lenses, spectacle lenses, and behavioral or optical interventions. Investors care because myopia control represents a growing, regulated healthcare market segment driven by long-term treatment demand, recurring product use, and potential reimbursement or clinical-trial milestones that can affect a company’s revenue and valuation. The concept is like brakes applied early to reduce future vision loss and related costs.

silicone hydrogel medical

"A novel premium 1-day silicone hydrogel (SiHy) technology"

A silicone hydrogel is a soft, rubbery material used to make contact lenses that combines water-loving gel with breathable silicone so oxygen can reach the eye. For investors, it matters because this technology drives product comfort, safety and longer wear times, which influence sales, regulatory approval, and competitive advantage—think of it like a breathable fabric for the eye that can determine whether customers and regulators prefer one lens over another.

toric medical

"the world's #1 toric design"

A toric lens is an eye lens—used as a contact lens or implanted during eye surgery—shaped to correct astigmatism, a common condition where the eye’s surface is curved more in one direction than another. Think of a rugby ball versus a soccer ball: a toric lens has different curvatures to match the eye’s uneven shape, so vision is clearer without extra corrective measures. For investors, toric products matter because they address a large, specialized market segment, often command premium pricing, and can be a key differentiator in regulatory approvals and commercial competition.

multifocal medical

"1-day SiHy toric multifocal contact lens"

Multifocal describes a disease, lesion, tumor, or abnormality that appears in several separate spots within an organ or body system rather than being limited to a single location. For investors, the term matters because multifocal findings can change clinical trial design, treatment complexity, regulatory review, prognosis, and potential market size for therapies; like multiple potholes across different lanes, they usually make diagnosis and treatment more complex and costly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The Vision Centre Brings Industry Leading Innovation to Accelerate Breakthroughs in Eye Care

ROCHESTER, N.Y., Sept. 23, 2026 /PRNewswire/ -- CooperVision today unveiled the grand opening of The Vision Centre, the company's new global innovation hub in Southampton, England, and announced six major product advancements that have been accelerated to launch over the next several years. The announcements were made as CooperVision brings together research and development, clinical expertise, pilot manufacturing, advanced technologies, and commercial capabilities to accelerate the development and commercialization of breakthrough solutions for patients and eye care professionals worldwide.

During the event, the company highlighted plans to introduce:

• The build-out of the world's first and only complete family of 1-day contact lenses for myopia control, built on the world's #1 toric design;
• A novel premium 1-day silicone hydrogel (SiHy) technology;
• A next-generation SiHy material in a high-performing monthly contact lens;
• A differentiated entry 1-day SiHy innovation to drive new fits;
• The most advanced 1-day SiHy toric multifocal contact lens;
• A new toric 1-day contact lens experience for astigmatic patients.

Together, these innovations represent one of the most ambitious product pipelines in CooperVision's history, reflecting the company's confidence in the future of contact lenses and its commitment to shaping the next era of vision care through science-led innovation.

"We're not satisfied with simply keeping pace with the evolution of eye care. We intend to help define what's next, while strengthening CooperVision's position as an innovative, technology-forward and consumer-connected vision care leader," said Jerry Warner, President of CooperVision.

The Vision Centre itself reflects CooperVision's continued investment in purposeful innovation and serves as a physical expression of the company's commitment to advancing vision for every eye. By strengthening the connections between scientific discovery, customer insight, product development, and commercialization, The Vision Centre is designed to help accelerate the delivery of meaningful innovations to eye care professionals and patients around the world.

The state-of-the-art facility is designed to create faster learning cycles and accelerate the path from idea to market-ready solution. The Centre further strengthens CooperVision's ability to leverage advanced modeling, simulation, analytics, and AI-enabled tools to support faster decision-making and future discoveries. The result is an ecosystem that combines scientific rigor, advanced technology, and deep customer understanding to help shape the future of eye care.

"The future of eye care will be shaped by collaboration, scientific advancement, and a deep understanding of the people who provide and benefit from our innovations," said Warner. "The Vision Centre provides an environment that helps our teams build on the strong collaboration that already exists across CooperVision, enabling faster learning, deeper integration, and accelerated discovery."

Spanning 9,940 square meters, the multi-story facility combines advanced laboratories, pilot manufacturing capability, a state-of-the-art clinic, customer engagement spaces, and technology-enabled environments.

The site will house approximately 350 employees and welcome colleagues, customers, partners, and other visitors from across the vision care industry through a range of learning, development, and collaboration programs.

For more information on CooperVision, visit www.coopervision.com.

About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is a global leader in contact lens innovation, dedicated to advancing vision at every stage of life. The company offers one of the industry's most comprehensive portfolios of soft and specialty contact lenses—including daily disposable, two-week and monthly options—with high–performance materials and optics across spherical, toric, and multifocal designs. With a strong heritage of addressing complex vision challenges such as childhood myopia, astigmatism, presbyopia, and irregular corneas, CooperVision combines purposeful research and development, state–of–the–art manufacturing, and deep practitioner partnerships to deliver clinically advanced solutions. Decades of experience and insight continue to shape the eye care profession and create meaningful advantages for both practitioners and wearers. For more information, visit www.coopervision.com.

About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.

Forward Looking Statement 

This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact are forward looking. In addition, all statements regarding anticipated growth in our revenues, anticipated market conditions, planned produce development and product launches, business transition expectations, regulatory plans, and expected results of operations are forward-looking. To identify these statements look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.

Media Contact
Laura DiCaprio, APR, McDougall Communications
laura@mcdougallpr.com or +1-585-434-2153

Heather Kowalczyk, APR, McDougall Communications
heather@mcdougallpr.com or +1-585-434-2148

View original content to download multimedia:https://www.prnewswire.com/news-releases/coopervision-powers-the-next-era-of-eye-care-with-new-global-vision-centre-and-major-pipeline-advancements-302887781.html

SOURCE CooperVision, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What capabilities are integrated into CooperVision's new Vision Centre?

The Vision Centre combines advanced laboratories, pilot manufacturing capability, a state-of-the-art clinic, customer engagement spaces, and technology-enabled environments. The company said this setup is designed to create faster learning cycles and accelerate the path from idea to market-ready eye care solutions.

How many people will work at The Vision Centre and who will it host?

The site will house approximately 350 employees and will welcome colleagues, customers, partners, and other visitors from across the vision care industry through a range of learning, development, and collaboration programs.